The CF Foundation recently provided an update on the following research trial.
Vertex 661 and ivacaftor (VX-661-106) in people with cystic fibrosis ages 12 and older with F508del-CFTR mutation
This is a Phase 3, multi-center trial that will look at the safety and effectiveness of the drug VX-661 in combination with ivacaftor. Researchers will test the drug’s effectiveness by measuring participant’s lung function in addition to other outcomes. This trial is for people ages 12 years and older who have two copies of the F508del-CFTR mutation. The trial will last approximately 6 months. It will require blood draws, sweat tests and lung function tests.
- CFF Link: https://tools.cff.org/Display/dsp_ClinicalResearchHTML.cfm?id=402&IDH=9233958
- ClinicalTrials.gov Link: https://www.clinicaltrials.gov/ct2/show/NCT02347657